On Jan. 31st, @LesTurnerALS will chat with genetic counselor @LayniedratchC about the role of a genetic counselor and address common questions about the genetics of ALS-FTD spectrum disorders, the genetic testing process, and more. Register here: https://t.co/kKJtznu2YQ

Have you ever considered genetic testing but aren't sure if it's right for you? Join our January ALS Learning Series with Laynie Dratch, genetic counselor at @PennfTDCenter . She will discuss the role of a genetic counselor, and address common questions https://t.co/Dw5NYP9IpB

Join us for our 4th annual virtual familial conference, Uncovering the Genetics of Familial FTD/ALS, on Wed., Feb. 21st, from 3PM-6PM EST. Hear from genetic counselors, neurologists, & social workers on the genetics of FTD/ALS. More info here: https://t.co/87wGPJnQab

What I love about this? It’s 💯 USEFUL and PRACTICAL - including acknowledging that sometimes Neurologists have to take a role genetic testing, given the shortage of genetic counselors - and @LayniedratchC helps us to get started!

Neurology Podcast: Dr. Gordon Smith & Laynie Dratch discuss integrating genetic testing into patient care for persons with #ALS & frontotemporal degeneration spectrum disorders. Listen now: https://t.co/0Ha5eOhHs2 Article: https://t.co/lwMQNUu3dB @gordonsmithMD @LayniedratchC

Enjoying the ALS & FTD communities coming together at the ALS/MND meeting with a great talk from @PennBiNDLab #alsmndsymp @PennFTDCenter

So grateful to have had the chance to present about ALS/FTD genetics & increasing access to genetics education and care at the Allied Professionals Forum @ALSMNDAlliance with wonderful colleagues Lauren from @LesTurnerALS and @PaulWicks from Sano Genetics!

@CEHaddadNP @End_The_Legacy @LesTurnerALS @sanogenetics @PaulWicks @LayniedratchC Cheers to the hard work done by all 3 presenters and their teams!

Great session! @End_The_Legacy @LesTurnerALS @sanogenetics @PaulWicks @LayniedratchC So proud to have supported this incredible work to increase access to testing and linking to support and trials for the genetic at risk community! #atriskALSFTD #ALS #FTD

"Having somebody understand what you're going through and explain it to you in ways that you can understand changed my life." Check out Penn FTDC genetic counselor @LayniedratchC's interview with @6abc on the life-changing benefits of genetic testing:

Having an inspiring and bittersweet day at the @PennFTDCenter memorial symposium for Murray Grossman. Here is some of Murray’s wisdom from @PennBiNDLab’s opening remarks for those who weren’t lucky enough to train with him.

Join us in person or online, Nov. 29th, 9AM-7PM EST for the Murray Grossman Memorial Symposium in honor of Penn FTDC founder Dr. Grossman. This event will feature scientific talks from former trainees and close colleagues. Registration and more info here: https://t.co/sGJ9m8nujo

🌍 Today marks the beginning of World FTD Awareness Week – a global call to #endFTD. The theme for today is self-care. Whether you're a caregiver, someone with a genetic link to FTD, or directly impacted by it, prioritizing your well-being matters. Here's how you can join in: 1️⃣

READ: 🧬"The lived experience of reconstructing identity in response to genetic risk of frontotemporal degeneration and amyotrophic lateral sclerosis." by #geneticcounselor @LayniedratchC and fellow Penn FTDC researchers. Read here:

Excited to share this wonderful tool for the ALS community that the @LesTurnerALS Foundation created! It was an honor & pleasure to work with them on this project. Looking forward to more collaborations to promote access to & education about genetics care!

(1/2) Another victory for the ALS community! Tofersen is the second treatment approved for ALS in less than a year and the third since 2017. This gene-based therapy is approved for treating people living with SOD1-ALS. Thanks to the entire community for your advocacy!

In honor of #dnaday, we’re reflecting on the late Dr. Grossman’s work as a major contributor to the study of familial FTD by pioneering genetic counseling & outreach to families at risk for early-onset neurodegenerative disease. Learn more from our center:

📣 Latest news! 📣 The @US_FDA have approved #Tofersen for the treatment of #SOD1 #MND in the US. This approval is based off data from the Phase 3 VALOR clinical trial. Mutations in the SOD1 gene account for ~2% of all MND cases. Find out more ⬇ https://t.co/oijgXNmXao

Happy #DNADay23! It truly is the perfect date.

Penn FTD Center’s co-director @PennBiNDLab honors the late Dr. Grossman and his achievements at the @allftd Investigator Meeting 2023 in Denver, Colorado this past weekend.